The p53-MDM2/MDMX axis - A chemotype perspective

被引：59
|
作者：
Khoury, Kareem [1 ]
Popowicz, Grzegorz M. [2 ]
Holak, Tad A. [2 ]
Doemling, Alexander [1 ]
机构：
[1] Univ Pittsburgh, Dept Pharmaceut Sci, Drug Discovery Inst, Pittsburgh, PA 15260 USA
[2] Max Planck Inst Biochem, D-8000 Munich, Germany
来源：
MEDCHEMCOMM | 2011年 / 2卷 / 04期
关键词：
PROTEIN-PROTEIN INTERACTION; SUPPRESSOR TRANSACTIVATION DOMAIN; SMALL-MOLECULE ANTAGONISTS; STRUCTURE-BASED DESIGN; WILD-TYPE P53; MDM2; INHIBITORS; CANCER-THERAPY; IN-VIVO; IDENTIFY DISRUPTORS; HDM2; ANTAGONISTS;
D O I：
10.1039/c0md00248h
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The protein-protein interaction (PPI) of the tumor suppressor p53 and its negative regulator MDM2 consists of the most intense studied PPI with a group of small molecular weight antagonists described and many more disclosed in patent literature. Due to the A-level structural insight into p53 interaction with MDM2 there is a reasonable understanding of the requirements of the molecules to bind. In contrast and despite the very close homology and 3-D similarity no potent MDMX antagonist has been disclosed up to date. The current review summarizes the different disclosed chemotypes for MDM2 including a discussion of the cocrystal structures. Structures and approaches to reconstitute functional p53 from mutated p53 are presented. Finally new screening methods and recent biotech deals based on p53 are discussed.
引用
收藏
页码：246 / 260
页数：15
相关论文
共 50 条
  • [1] p53-MDM2 and MDMX Antagonists
    Neochoritis, Constantinos
    Estrada-Ortiz, Natalia
    Khoury, Kareem
    Domling, Alexander
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 167 - 187
  • [2] Comparative study of the p53-mdm2 and p53-MDMX interfaces
    Böttger, V
    Böttger, A
    Garcia-Echeverria, C
    Ramos, YFM
    van der Eb, AJ
    Jochemsen, AG
    Lane, DP
    ONCOGENE, 1999, 18 (01) : 189 - 199
  • [3] Comparative study of the p53-mdm2 and p53-MDMX interfaces
    Volker Böttger
    Angelika Böttger
    Carlos Garcia-Echeverria
    Yolande FM Ramos
    Alex J van der Eb
    Aart G Jochemsen
    David P Lane
    Oncogene, 1999, 18 : 189 - 199
  • [4] Stochastic Modeling and Simulation of the p53-MDM2/MDMX Loop
    Cai, Xiaodong
    Yuan, Zhi-Min
    JOURNAL OF COMPUTATIONAL BIOLOGY, 2009, 16 (07) : 917 - 933
  • [5] Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis
    Ting Zhou
    Zhiqiang Ke
    Qianqian Ma
    Jiani Xiang
    Meng Gao
    Yongqi Huang
    Xiyao Cheng
    Zhengding Su
    Scientific Reports, 13
  • [6] Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis
    Zhou, Ting
    Ke, Zhiqiang
    Ma, Qianqian
    Xiang, Jiani
    Gao, Meng
    Huang, Yongqi
    Cheng, Xiyao
    Su, Zhengding
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] Relevance of the p53-MDM2 axis to aging
    Wu, Danyi
    Prives, Carol
    CELL DEATH AND DIFFERENTIATION, 2018, 25 (01): : 169 - 179
  • [8] Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction
    Lemos, Agostinho
    Leao, Mariana
    Soares, Joana
    Palmeira, Andreia
    Pinto, Madalena
    Saraiva, Lucilia
    Sousa, Maria Emilia
    MEDICINAL RESEARCH REVIEWS, 2016, 36 (05) : 789 - 844
  • [9] Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions
    Munisamy, Murali
    Mukherjee, Nayonika
    Thomas, Levin
    Pham, Amy Trinh
    Shakeri, Arash
    Zhao, Yusheng
    Kolesar, Jill
    Rao, Praveen P. N.
    Rangnekar, Vivek M.
    Rao, Mahadev
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (12): : 5762 - +
  • [10] Systematic Mutational Analysis of Peptide Inhibition of the p53-MDM2/MDMX Interactions
    Li, Chong
    Pazgier, Marzena
    Li, Changqing
    Yuan, Weirong
    Liu, Min
    Wei, Gang
    Lu, Wei-Yue
    Lu, Wuyuan
    JOURNAL OF MOLECULAR BIOLOGY, 2010, 398 (02) : 200 - 213
12345